North America Neuroendocrine Tumors Market to 2032
Overview
The North America Neuroendocrine Tumors Market is expected to reach a 3.97 USD Billion by 2032 and is projected to grow at a CAGR of 16.67% from 2025 to 2032.
Revenue, 2024 (USD Billion)
1.73
Forecast, 2032 (USD Billion)
3.97
CAGR, 2024 - 2032
16.67%
Report Coverage
North America
North America Neuroendocrine Tumors Market 2018-2032 USD Billion
North America Neuroendocrine Tumors Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 1.73 USD Billion
- Projected Market Size (2032): 3.97 USD Billion
- CAGR (2025-2032): 16.67%
Key Findings of North America Neuroendocrine Tumors Market
- The North America Neuroendocrine Tumors Market was valued at 1.73 USD Billion in 2024.
- The North America Neuroendocrine Tumors Market is likely to grow at a CAGR of 16.67% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Non-Funtional NET in Classification Segment accounted for the largest share of the market with a revenue of 1.23 USD Billion
- The fastest growing segment Oral in Route of Administration Segment grew Fastest with a CAGR of 26.89% during the forecast period from 2024 to 2032.
North America Neuroendocrine Tumors Market Scope
North America Neuroendocrine Tumors Market Segmentation & Scope
Distribution Channel
- Others
- Online Pharmacy
- Retail Sales
- Hospital Pharmacy
- Direct Tender
End User
- Others
- Home Healthcare
- Radiation Centers
- Speciality Clinics
- Hospitals
Type
- Treatment
- Diagnosis
Route of Administration
- Parenteral
- Oral
Grade
- Grade 1 (Low-Grade Tumor)
- Grade 3 (High-Grade Tumor)
- Grade 2 (Intermediate-Grade Tumor)
Site
- Pancreas
- Lungs
- Gastrointestinal Tract (GI)
Classification
- Funtional NET
- Non-Funtional NET
North America Neuroendocrine Tumors Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 1.73 USD Billion |
| Market Value in 2032 | 3.97 USD Billion |
| CAGR (2025-2032) | 16.67% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End User,Type,Route of Administration,Grade ,Site,Classification |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 1.73 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 1,574.11 USD Million in 2024.
Segments and Scope
-
North America Neuroendocrine Tumors Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 623.00 USD Billion in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 16.98 % in forecast period 2025-2032.
-
North America Neuroendocrine Tumors Market to 2032, By End User
- Hospitals is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 683.74 USD Billion in the year 2024.
- Speciality Clinics is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 15.34 % in forecast period 2025-2032.
-
North America Neuroendocrine Tumors Market to 2032, By Type
- Diagnosis is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 1.04 USD Billion in the year 2024.
- Treatment is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 11.55 % in forecast period 2025-2032.
-
North America Neuroendocrine Tumors Market to 2032, By Route of Administration
- Oral is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 105.71 USD Billion in the year 2024.
- Oral is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 26.89 % in forecast period 2025-2032.
-
North America Neuroendocrine Tumors Market to 2032, By Grade
- Grade 2 (Intermediate-Grade Tumor) is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 951.75 USD Billion in the year 2024.
- Grade 2 (Intermediate-Grade Tumor) is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 17.22 % in forecast period 2025-2032.
-
North America Neuroendocrine Tumors Market to 2032, By Site
- Gastrointestinal Tract (GI) is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 933.42 USD Billion in the year 2024.
- Gastrointestinal Tract (GI) is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 18.96 % in forecast period 2025-2032.
-
North America Neuroendocrine Tumors Market to 2032, By Classification
- Non-Funtional NET is the largest segment in North America Neuroendocrine Tumors Market to 2032 with a revenue of 1.23 USD Billion in the year 2024.
- Non-Funtional NET is the Fastest growing segment in North America Neuroendocrine Tumors Market to 2032 with a Growth rate of 17.20 % in forecast period 2025-2032.
North America Neuroendocrine Tumors Market Company Share Analysis
| Company Name |
|
||
| Mylan N.V. | |||
| Novartis AG | |||
| Lupin | |||
| Lilly | |||
| Thermo Fisher Scientific Inc. | |||
North America Neuroendocrine Tumors Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Neuroendocrine Tumors Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Neuroendocrine Tumors Market is segmented based on Segmentation Distribution Channel,End User,Type,Route of Administration,Grade ,Site,Classification.
North America Neuroendocrine Tumors Market was valued at USD 1.73(Revenue in USD Billion) in 2020.
North America Neuroendocrine Tumors Market is projected to grow at a CAGR of 16.67% during the forecast period of 2024 to 2032.
The Non-Funtional NET segment is expected to dominate the North America Neuroendocrine Tumors Market, holding a largest market share of 1.23 USD Billion in 2024
North America Neuroendocrine Tumors Market Scope
North America Neuroendocrine Tumors Market Segmentation & Scope
Distribution Channel
- Others
- Online Pharmacy
- Retail Sales
- Hospital Pharmacy
- Direct Tender
End User
- Others
- Home Healthcare
- Radiation Centers
- Speciality Clinics
- Hospitals
Type
- Treatment
- Diagnosis
Route of Administration
- Parenteral
- Oral
Grade
- Grade 1 (Low-Grade Tumor)
- Grade 3 (High-Grade Tumor)
- Grade 2 (Intermediate-Grade Tumor)
Site
- Pancreas
- Lungs
- Gastrointestinal Tract (GI)
Classification
- Funtional NET
- Non-Funtional NET
Frequently Asked Questions
The North America Neuroendocrine Tumors Market is segmented based on Segmentation Distribution Channel,End User,Type,Route of Administration,Grade ,Site,Classification.
North America Neuroendocrine Tumors Market was valued at USD 1.73(Revenue in USD Billion) in 2020.
North America Neuroendocrine Tumors Market is projected to grow at a CAGR of 16.67% during the forecast period of 2024 to 2032.
The estimated market value of the North America Neuroendocrine Tumors Market for final year is USD 3.97 (USD Billion).
North America Neuroendocrine Tumors Market Company Profiling
Frequently Asked Questions
The North America Neuroendocrine Tumors Market is segmented based on Segmentation Distribution Channel,End User,Type,Route of Administration,Grade ,Site,Classification.
North America Neuroendocrine Tumors Market was valued at USD 1.73(Revenue in USD Billion) in 2020.
North America Neuroendocrine Tumors Market is projected to grow at a CAGR of 16.67% during the forecast period of 2024 to 2032.
The estimated market value of the North America Neuroendocrine Tumors Market for final year is USD 3.97 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.